Panel

Information on Panel composition and the Conflict of Interest Policy can be found in Methods Table 1; financial relationships between Panel members and commercial firms are listed
in the Disclosure Table.

Chairs

Raymond T. Chung, MD

Harvard Medical School

Arthur Y. Kim, MD

Harvard Medical School

Susanna Naggie, MD, MHS

Duke University School of Medicine
Durham VA Medical Center

Hugo E. Vargas, MD

College of Medicine, Mayo Clinic

Panel Members

Andrew I. Aronsohn, MD

University of Chicago Medical Center

Timothy R. Morgan, MD

Veterans Affairs Long Beach Healthcare System

Debika Bhattacharya, MD

University of California Los Angeles

Marion G. Peters, MD

University of California San Francisco

Oluwaseun O. Falade-Nwulia, MBBS, MPH

Johns Hopkins University School of Medicine

Daniel Raymond

Harm Reduction Coalition

Robert J. Fontana, MD

University of Michigan Medical School

Eliot W. Godofsky, MD, FACP

Bach and Godofsky, Infectious Diseases

K. Rajender Reddy, MD

Hospital of the University of Pennsylvania

Theo Heller, MD

National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health

Andrew Reynolds

Project Inform

Scott D. Holmberg, MD** +

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention

Michael S. Saag, MD

The University of Alabama at Birmingham

Jennifer J. Kiser, PharmD

University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences

John D. Scott, MD, MSc, FIDSA

Hepatitis and Liver Clinic
University of Washington

Tracy Swan

Treatment Action Group

Benjamin P. Linas, MD, MPH

Boston University School of Medicine

Norah A. Terrault, MD

University of California San Francisco

Kristen M. Marks, MD

Weill Cornell Medical College

John B. Wong, MD

Tufts University School of Medicine

Marc G. Ghany, MD, MHSc* **

National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health

*Individual employees of the National Institutes of Health (NIH) have participated in the planning and development of the Guidance, although the NIH is not an official sponsor.

**The views expressed by the participants do not necessarily represent the opinions of the Centers for Disease Control and Prevention, the National Institutes of Health, or the Department of Health and Human Services.
+ Non-voting Panel members

Previous Panel Chairs

Gary L. Davis, MD

Baylor University Medical Center (retired)
2013 - 2015

Michael S. Saag, MD

The University of Alabama at Birmingham
2013 - 2015

Donald M. Jensen, MD

University of Chicago Medical Center (retired)
2013 - 2014

David L. Thomas, MD, MPH

The Johns Hopkins University School of Medicine
2013 - 21015

Henry Masur, MD* **

National Institutes of Health
2013 - 2015

Previous Panel Members

Jordan J. Feld, MD, MPH

Toronto Western Hospital Liver Center
2013 - 2015

Robert T. Schooley, MD

University of California San Diego
2013 - 2015

Kenneth E. Sherman, MD, PhD

University of Cincinnati College of Medicine
2013 - 2015

Camilla S. Graham, MD, MPH

TREK Therapeutics, PBC
2014 - 2015

Mark S. Sulkowski, MD

The Johns Hopkins University School of Medicine
2013 - 2015

Kiren Mitruka, MD, MPH** +

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
2013 - 2015

John W. Ward, MD** +

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
2013 - 2015

Michael R. Charlton, MD

Intermountain Medical Center
2013 - 2016

Shyam Kottilil, MD, PhD

Division of Infectious Diseases
Institute of Human Virology/University of Maryland
2013 - 2016

Paul Martin, MD

University of Miami School of Medicine
2013 - 2016

Nancy S. Reau, MD

Rush University Medical Center
2013 - 2016

David L. Wyles, MD

University of California San Diego
2013 - 2016

Contributors and Technical Advisors

Saleem Kamili, PhD**

Division of Viral Hepatitis
Deputy Chief, Laboratory Branch, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention

For contributing to development of the Testing and Linkage to Care Table 1: FDA-approved, Commercially Available Anti-HCV Screening Assays

Rachel J. Wilson**

Division of Viral Hepatitis
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention

For comprehensive copy editing and styling of the final Guidance

Judith Welsh, BS, MLS* **

Clinical Informationist
NIH Library
National Institutes of Health

For performing comprehensive literature searches to identify the evidence used to prepare the Guidance

HCV Guidance Project Management

Sheila A. Tynes, MHA

Program Director

Vincent Keane

Website Publication and Management

Acknowledgement

The International Antiviral Society–USA (IAS–USA) served as the collaborating partner for the HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C from the project’s inception in mid- 2013 through 2015. IAS-USA was responsible for managing the writing panel and the guidance development process. A representative from IAS–USA also served as a co-chair of the HCV Guidance Panel. Due to priorities related to their core mission, IAS-USA elected to end their relationship as collaborating partner on December 31. AASLD and IDSA recognize IAS-USA’s tremendous contribution to the HCV Guidance and the creation and maintenance of www.hcvguidelines.org. Special appreciation is extended to the following individuals for their outstanding service:

  • Michael Saag, MD
  • Donna Jacobsen
  • Cindy Downing
  • Michelle Valderama
  • Jennezel Peneda
  • Rachel Lastra

You are using an outdated browser, please upgrade your browser or download Firefox or Chrome.